Changes in Quality of Life After Treatment for Non-Melanoma Skin Cancer: A Prospective Cohort Study
4 affiliations
- 1Department of Dermatology, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Türkiye
- 2Department of Dermatology, İznik State Hospital, Bursa 16890, Türkiye
- 3Department of Plastic Reconstructive and Aesthetic Surgery, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Türkiye
- 4Department of Public Health, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Türkiye
Abstract
Background/Objectives: Non-melanoma skin cancer (NMSC), particularly basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), may adversely affect quality of life (QoL), especially in cosmetically sensitive areas. This study aimed to identify factors associated with QoL in patients with NMSC and to evaluate changes in dermatology- and skin cancer-specific QoL following treatment. Methods: This prospective study included 169 patients with NMSC evaluated at baseline and 3 months after treatment using the Dermatology Life Quality Index (DLQI) and Skin Cancer Quality of Life Impact Tool (SCQOLIT). Factors associated with baseline QoL and changes according to treatment modality and histological subtype were analysed. Results: The mean age was 69.2 ± 11.85 years; 82.8% had BCC and 17.2% had SCC. Mean DLQI scores decreased from 2.29 ± 2.81 to 0.34 ± 0.75 and SCQOLIT scores from 4.78 ± 5.53 to 1.20 ± 1.76 at 3 months (both p < 0.001). Lower educational level was associated with higher baseline DLQI scores, whereas younger age and higher socioeconomic status were associated with higher and lower baseline SCQOLIT scores, respectively; these associations persisted in sensitivity analyses. The associations of younger age, female sex, and SCC histology with higher DLQI scores were less robust. SCC patients had higher baseline DLQI scores than BCC patients (3.66 ± 4.82 vs. 2.01 ± 2.10, p = 0.040), but this difference was no longer statistically significant at 3 months. QoL improved following both surgical and medical treatment, with no significant differences in the magnitude of improvement among surgical or medical treatment types. Conclusions: QoL improved significantly within 3 months after NMSC treatment. Different factors were associated with baseline DLQI and SCQOLIT scores, suggesting that these instruments may capture complementary aspects of QoL. Their combined use may provide a more comprehensive assessment of patients with NMSC.
Related
- Dietary Intake During Breast Cancer Treatment and Its Association with Changes in Cardiometabolic Risk Markers and Psychological Outcomes in Women with Breast Cancer: A Prospective Cohort Study Protocol
- Depression and Anxiety in Melanoma Patients and Their Relationships with Dermatology-Related Quality of Life: A Prospective Observational Cross-Sectional Study
- Anthocyanin-Rich Freeze-Dried Berry Supplementation in Patients Undergoing Colorectal Cancer Treatment: A Prospective Single-Arm Pilot Study of Tolerability and Longitudinal Inflammatory Biomarker Changes
- Score interpretation thresholds for the European Organisation for Research and Treatment of Cancer thyroid cancer quality of life questionnaire (EORTC QLQ-THY34). An international prospective study.
- Geriatric Assessment-Based Stratification to Evaluate Treatment Intensity, Quality of Life, and Survival in Older Patients With Metastatic Colorectal Cancer: Protocol for a Prospective Observational Study.
BibTeX
@article{ozturk2026changes,
title = {{Changes in Quality of Life After Treatment for Non-Melanoma Skin Cancer: A Prospective Cohort Study}},
author = {Ferdi Öztürk and Zehra Neslişah Unan Bacak and Egenaz Şenol Okan and Ümmühan Şeker and Kenan Aydoğan and Serkan Yazici and Süleyman Çeçen and Beyhan Cengiz Özyurt and Hayriye Sarıcaoğlu},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207890},
url = {https://www.mdpi.com/2077-0383/15/20/7890},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Changes in Quality of Life After Treatment for Non-Melanoma Skin Cancer: A Prospective Cohort Study
AU - Ferdi Öztürk
AU - Zehra Neslişah Unan Bacak
AU - Egenaz Şenol Okan
AU - Ümmühan Şeker
AU - Kenan Aydoğan
AU - Serkan Yazici
AU - Süleyman Çeçen
AU - Beyhan Cengiz Özyurt
AU - Hayriye Sarıcaoğlu
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207890
UR - https://www.mdpi.com/2077-0383/15/20/7890
AB - Background/Objectives: Non-melanoma skin cancer (NMSC), particularly basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), may adversely affect quality of life (QoL), especially in cosmetically sensitive areas. This study aimed to identify factors associated with QoL in patients with NMSC and to evaluate changes in dermatology- and skin cancer-specific QoL following treatment. Methods: This prospective study included 169 patients with NMSC evaluated at baseline and 3 months after treatment using the Dermatology Life Quality Index (DLQI) and Skin Cancer Quality of Life Impact Tool (SCQOLIT). Factors associated with baseline QoL and changes according to treatment modality and histological subtype were analysed. Results: The mean age was 69.2 ± 11.85 years; 82.8% had BCC and 17.2% had SCC. Mean DLQI scores decreased from 2.29 ± 2.81 to 0.34 ± 0.75 and SCQOLIT scores from 4.78 ± 5.53 to 1.20 ± 1.76 at 3 months (both p < 0.001). Lower educational level was associated with higher baseline DLQI scores, whereas younger age and higher socioeconomic status were associated with higher and lower baseline SCQOLIT scores, respectively; these associations persisted in sensitivity analyses. The associations of younger age, female sex, and SCC histology with higher DLQI scores were less robust. SCC patients had higher baseline DLQI scores than BCC patients (3.66 ± 4.82 vs. 2.01 ± 2.10, p = 0.040), but this difference was no longer statistically significant at 3 months. QoL improved following both surgical and medical treatment, with no significant differences in the magnitude of improvement among surgical or medical treatment types. Conclusions: QoL improved significantly within 3 months after NMSC treatment. Different factors were associated with baseline DLQI and SCQOLIT scores, suggesting that these instruments may capture complementary aspects of QoL. Their combined use may provide a more comprehensive assessment of patients with NMSC.
SN - 2077-0383
ER -